Obagi

Faced with $30 billion in debt, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has few options at its disposal. Among the company's options to reduce its debt load includes selling off some of its drug assets, or selling complete business units. According to a report by Reuters, Valeant is...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has hired investment bankers to explore its strategic options, according to Reuters. Reuters, citing "people familiar with the matter," reported that Valeant has tapped bankers and advisors at Goldman Sachs and Centerview Partners Holdings...